Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


21.01.2019

5 BMC Cancer
2 Gynecol Oncol
1 Hum Pathol
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. SUZUKI Y, Tokinaga-Uchiyama A, Mizushima T, Maruyama Y, et al
    Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment.
    BMC Cancer. 2018;18:973.
    PubMed     Text format     Abstract available

  2. SANCHEZ VEGA JF, Murillo Bacilio MDR, Vintimilla Condoy AS, Palta Gonzalez AM, et al
    Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker.
    BMC Cancer. 2018;18:587.
    PubMed     Text format     Abstract available

  3. LIM MC, Won YJ, Lim J, Salehi T, et al
    Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study.
    BMC Cancer. 2018;18:800.
    PubMed     Text format     Abstract available

  4. NIEUWENHUYZEN-DE BOER GM, Hofhuis W, Reesink-Peters N, Ewing-Graham PC, et al
    Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
    BMC Cancer. 2019;19:58.
    PubMed     Text format     Abstract available

  5. BALOCH T, Lopez-Ozuna VM, Wang Q, Matanis E, et al
    Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    BMC Cancer. 2019;19:44.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  6. FABBRO M, Moore KN, Dorum A, Tinker AV, et al
    Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31473.
    PubMed     Text format     Abstract available

  7. MCCUAIG JM, Tone AA, Maganti M, Romagnuolo T, et al
    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(18)31541.
    PubMed     Text format     Abstract available


    Hum Pathol

  8. SHEN W, Niu N, Lawson B, Qi L, et al
    GATA6: a new predictor for prognosis in ovarian Cancer.
    Hum Pathol. 2019 Jan 8. pii: S0046-8177(19)30003.
    PubMed     Text format     Abstract available


    PLoS One

  9. EAVARONE DA, Al-Alem L, Lugovskoy A, Prendergast JM, et al
    Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.
    PLoS One. 2018;13:e0201314.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  10. GARTUNG A, Yang J, Sukhatme VP, Bielenberg DR, et al
    Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.
    Proc Natl Acad Sci U S A. 2019 Jan 15. pii: 1803999116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: